Clene Inc. (NASDAQ:CLNN – Get Rating) Director David J. Matlin bought 132,891 shares of the business’s stock in a transaction on Wednesday, April 20th. The stock was acquired at an average cost of $3.01 per share, for a total transaction of $400,001.91. Following the acquisition, the director now directly owns 1,844,288 shares of the company’s stock, valued at $5,551,306.88. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
CLNN opened at $2.87 on Friday. The business’s 50 day moving average is $3.06 and its 200-day moving average is $4.01. The stock has a market cap of $181.52 million, a PE ratio of -13.04 and a beta of 0.11. The company has a current ratio of 9.06, a quick ratio of 9.05 and a debt-to-equity ratio of 1.52. Clene Inc. has a twelve month low of $2.36 and a twelve month high of $17.82.
Clene (NASDAQ:CLNN – Get Rating) last released its quarterly earnings results on Friday, March 11th. The company reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.23. As a group, analysts forecast that Clene Inc. will post -0.71 EPS for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CLNN. Morgan Stanley increased its stake in shares of Clene by 110.5% during the first quarter. Morgan Stanley now owns 2,105 shares of the company’s stock valued at $27,000 after acquiring an additional 1,105 shares during the period. Bank of America Corp DE increased its stake in shares of Clene by 7,045.1% during the second quarter. Bank of America Corp DE now owns 5,859 shares of the company’s stock valued at $66,000 after acquiring an additional 5,777 shares during the period. Wells Fargo & Company MN increased its stake in shares of Clene by 9,823.7% during the second quarter. Wells Fargo & Company MN now owns 13,000 shares of the company’s stock valued at $146,000 after acquiring an additional 12,869 shares during the period. Soltis Investment Advisors LLC acquired a new position in shares of Clene during the third quarter valued at approximately $1,495,000. Finally, Morgan Jess S & Co. Inc. acquired a new position in shares of Clene during the third quarter valued at approximately $203,000. 15.24% of the stock is currently owned by institutional investors.
Clene Company Profile (Get Rating)
Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
- Get a free copy of the StockNews.com research report on Clene (CLNN)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.